Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Free Cash Flow (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Free Cash Flow for 6 consecutive years, with -$7.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 26.22% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$25.4 million through Dec 2025, down 19.64% year-over-year, with the annual reading at -$25.4 million for FY2025, 19.64% down from the prior year.
  • Free Cash Flow hit -$7.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$5.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.2 million in Q3 2023 to a low of -$14.8 million in Q1 2022.
  • Historically, Free Cash Flow has averaged -$7.9 million across 5 years, with a median of -$6.9 million in 2023.
  • Biggest five-year swings in Free Cash Flow: soared 73.85% in 2023 and later crashed 75.26% in 2024.
  • Year by year, Free Cash Flow stood at -$7.5 million in 2021, then plummeted by 39.97% to -$10.4 million in 2022, then skyrocketed by 55.14% to -$4.7 million in 2023, then fell by 18.71% to -$5.6 million in 2024, then decreased by 26.22% to -$7.0 million in 2025.
  • Business Quant data shows Free Cash Flow for IMDX at -$7.0 million in Q4 2025, -$5.6 million in Q3 2025, and -$6.6 million in Q2 2025.